United Kingdom · Question · Written question
UIN 116002
Rare Cancers: Medical Treatments
Introduced
25 February 2026
Last action
4 March 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
4 March 2026
Summary
To ask the Secretary of State for Health and Social Care, whether the joint accelerated approvals pathway operated by the National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency will enable tumour-agnostic
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 February 2026
Written question
To ask the Secretary of State for Health and Social Care, whether the joint accelerated approvals pathway operated by the National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency will enable tumour-agnostic
Source: Commons
4 March 2026
Answer
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2026-02-25/116002
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1885040
- uk · wq-1885040 · source updated 4 March 2026